Dermatology Times: FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD
by Marie Bosslett
Alphyn Biologics announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin hydrogel, which is used to treat mild to moderate atopic dermatitis (AD).
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195